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Despite considerable progress in genome- 
and proteome-based high-throughput 
screening methods and rational drug design, 
the number of successful single target drugs 
did not increase appreciably during the past 
decade. Network models suggest that partial 
inhibition of a surprisingly small number of 
targets can be more efficient than the 
complete inhibition of a single target. This 
and the success stories of multi-target drugs 
and combinatorial therapies led us to 
suggest that systematic drug design 
strategies should be directed against 
multiple targets. We propose that the final 
effect of partial, but multiple drug actions 
might often surpass that of complete drug 
action at a single target. The future success 
of this novel drug design paradigm will 
depend not only on a new generation of 
computer models to identify the correct 
multiple hits and their multi-fitting, low-
affinity drug candidates but also on more 
efficient in vivo testing.  
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Multi-target drugs help us more often than 
we think 
Drug development strategies have been influenced 
profoundly by the wealth of potential targets 
offered by genome projects. At present, the goal is 
to: (i) find a target of suitable function; (ii) identify 
the ‘best-binder’ by high-throughput screening of 
large combinatorial libraries and/or by rational drug 
design based on the three-dimensional structure of 
the target; (iii) provide a set of proof-of-principle 
experiments; and (iv) develop a technology 
platform projecting to potential clinical applications 
(Figure 1a). However, despite all the careful studies 
and the considerable drug-development efforts 
undertaken, the number of successful drugs and 
novel targets did not increase appreciably during 
the past decade [1,2]. Several highly efficient 
drugs, such as non-steroidal anti-inflammatory 
drugs (NSAIDs), salicylate, metformin or 
Gleevec™, affect many targets simultaneously. 
Furthermore, combinatorial therapy, which 
represents another form of multi-target drugs, is 
used increasingly to treat many types of diseases, 
such as AIDS, cancer and atherosclerosis [3-5]. 
Snake and spider venoms are both multi-component 
systems and plants also employ batteries of various 
factors to fence off pathogenic attack; thus the use 
of multiple molecules is apparently an evolutionary 
success story. Finally, traditional medical 
treatments often use multi-component extracts of 
natural products. Based on these examples and on 
our recent results of network analysis [6] here we 
propose that systematic drug design strategies 
should be directed against multiple targets, and this 
novel drug design paradigm might often result in 
the development of more efficient molecules than 
the currently favored single-target drugs. 
 
Single hits are often insufficient 
Agents that affect one target only (‘single-hits’) 
might not always affect complex systems in the 
desired way even if they completely change the 
behavior of their immediate target. For example, 
single targets might have ‘back-up’ systems that are 
sometimes different enough not to respond to the 
same drug, and many cellular networks are robust 
and prevent major changes in their outputs despite 
dramatic changes in their constituents [7,8]. These 
considerations are independent of whether or not 
the pharmacological agent inhibits or activates its 
target. 
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 Multi-target drugs are often low-affinity 
binders 
Development of a multi-target drug is likely to 
produce a drug that interacts with lower affinity 
than a single target drug because it is unlikely that a 
small, drug-like molecule will bind to a variety of 
different targets with equally high affinity. 
However, low-affinity drug binding is apparently 
not a disadvantage. For example, memantine (a 
drug used to treat Alzheimer’s disease) and other 
multi-target non-competitive NMDA receptor 
antagonists show that low-affinity, multi-target 
drugs might have a lower prevalence and a reduced 
range of side-effects than high-affinity, single-
target drugs [9,10]. Does low-affinity binding mean 
that the interaction of the drug with the target is 
non-productive? Not necessarily. Most components 
of the cellular protein, signaling and transcriptional 
networks are in ‘weak linkage’ with each other 
[10]. A ‘weak linker’ is an interacting partner that 
binds with low affinity or only transiently to the 
other partner. This concept is used mainly in the 
context of networks and can refer both to physical 
interactions and influences of a network element on 
another network element. In metabolic networks, 
weak links are those reactions, which have a low 
flux [11-14]. In this paper we define weak linkers 
as small molecules and drugs that interact with 
cellular proteins using low-affinity physical 
interactions. Thus, most multi-target drugs are 
weak linkers. Because most links in cellular 
networks are weak, a low-affinity multi-target drug 
might be sufficient to achieve a significant 
modification. However, drug efficacy is also a 
highly important issue, and the question arises: can 
the multiplication of low-affinity binding affect the 
complex cellular system equally or better than the 
high-affinity and selective binding to a single 
target? 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.  Drug design. (a) In the current single-target drug design paradigm the goal is to: (i) find a target gene, 
regulatory DNA sequence, protein or other macromolecule (such as non-coding RNA) of suitable function; (ii) 
identify the ‘best-binder’ by high-throughput screening of large combinatorial libraries (in vitro) and/or by 
rational drug design based on the three-dimensional structure of the target (in silico); (iii) provide a set of proof-
of-principle experiments (lab tests); and (iv) develop a technology platform that predicts potential clinical 
applications. (b,c) In the network models, the drug candidate molecule (pharmacon) binds to its target, which is 
a part of a cellular network. The effect of a drug candidate on a prokaryotic genetic regulatory network that 
consists of regulator proteins (1 and 2) that affect the action of operons (DNA sequences coding at least one 
protein) is shown. However, the network approach to study the efficiency of drug action can also be applied to 
eukaryotic genetic regulatory networks, and metabolic or signaling networks. (b) The effect of complete 
inactivation of a single target (regulator 1), which is the usual outcome of the current single-target drug design 
paradigm, is shown. The effects of regulator 1 are inhibited completely. (c) The partial inactivation of multiple 
targets (regulators 1 and 2), which we propose as a novel drug design paradigm resulting in the development of 
efficient multi-target drugs, is shown. (The activation of a single target or multiple targets would essentially 
result in a similar, but reversed action.) In this case, only some of the effects of the regulators are inhibited. Kd,1 
and Kd,2 (c) usually represent an interaction of lower affinity than that indicated by Kd. A method for drug-
efficiency analysis using the network approaches (b,c) is described in Box 1. 
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 Box 1. Analysis of the effect of multi-target attacks in a network-based model 
 
 
 
In the network model of pharmacological actions, 
elements of the network represent various targets 
(proteins, RNA sequences or DNA sequences), whereas 
the links that connect them, represent their interactions 
within the cell. Here, the efficient drug-induced 
inhibition of a single target is modeled by the elimination 
of all interactions at the representing element (Figure Ia, 
complete knockout). Partial inactivation of a drug-target 
in the network-context can be modeled in two different 
ways: the drug either knocks out a proportion (e.g. half) 
of the interactions of a given protein [Figure Ib(i); partial 
knockout] or the drug attenuates all interactions of a 
protein [Figure Ib(ii); attenuation]. In the ‘attenuation’ 
experiments an attack on a link is modelled by depicting 
the respective connection (link) as 50% (dashed line) or 
25% (dotted line) of the original. Finally, a distributed, 
system-wide attack can affect any protein-protein 
interaction (any link) within the network. Again, two 
simplified strategies can be used either knocking out 
[Figure Ic(i); distributed knockout] or attenuating [Figure 
Ic(ii); distributed attenuation] individual interactions 
(links) of the network. All of these described attacks 
correspond to inhibition scenarios, where functions are 
entirely or partially blocked in a manner similar to what 
happens when an antibiotic acts on a pathogen. The 
effect of a drug that restores the normal function of an 
inhibited receptor can be modeled by analogous steps 
carried out in reverse. Low-affinity, multi-target drugs 
might achieve the modification of network interactions 
better if they are allosteric inhibitors or activators. 
However, in case of low-affinity, weak interactions 
(which is the case of most interactions in the cell [11]) a 
competitive inhibition might also be efficient. 
 
Attacks decrease network integrity and make the 
interactions between distant elements more complicated 
[37]. The corresponding network property can be 
captured by a computable quantity, called network 
efficiency (Figure Id), which is a global measure of 
network integrity related to the shortest path length 
among each pair of elements within the network. The 
network efficiency is expressed as the sum of the 
reciprocals of the shortest (directed) path lengths between 
all pairs of elements [Figure Id(i), where N denotes the 
number of elements in the network] [38]. The path length 
values for the network shown in Figure Id(ii) are given 
by the dij distance matrix [where the numbered 
interactions are shown in bold, and the numbers within 
the grid represent the number of steps in the interaction 
(e.g. ‘1’ denotes a direct interaction between two 
elements, ‘2’ denotes that two elements interact via two 
other intermediary elements)] [Figure Id(iii)]. Numbers 
shown in red are those paths that disappear when the two 
links marked in Figure Id(ii) are inhibited completely. In 
the case of attenuation, the path lengths concerned are 
multiplied by a weight of 2 or 4 depending on the extent 
of attenuation (50% or 25%) and the one with a minimum 
weight is selected [6,38]. If the two links marked by red 
X are deleted, the network efficiency decreases to 57.5%. 
The two major assumptions of the use of network 
efficiency as a measure for drug efficiency are that: (i) a 
mechanism targeted by a drug can be represented as a 
network; and (ii) all elements of this network must 
interact for the function of the targeted mechanism. 
Having more detailed information on the specific role 
and importance of the individual network elements, the 
efficiency of single-target and multi-target drugs can be 
compared more precisely. We give examples for these 
dynamic network models [20-22,25-33] in the text. 
 
 
Analysis of drug targets using a network 
approach  
Most studies that examine drug-development 
strategies are based on target-driven approaches, 
where an efficient method to combat a certain 
disease was sought. The network approach (Figure 
1b-c) examines the effect of drugs in the context of 
a network of relevant protein-protein interactions 
[12-14]. In these network models each element 
represents a protein, and each link corresponds to 
an interaction between two proteins of the cell. In 
this model the efficient drug-induced inhibition of a 
single target means that the interactions around a 
given target are eliminated, whereas partial 
inhibition can be modeled as a partial knockout of 
the interactions of the target (Box 1). In addition to 
protein-interaction networks, regulatory, metabolic 
and signaling networks can be subjected to a 
similar analysis. 
 
The network approach now has a tradition in drug 
target analysis. Comparison of transcriptional 
networks from various genomes helps to identify 
the function of novel proteins and thus increases 
the number of potential drug targets [15,16]. 
Proteomic analysis of protein-protein interactions 
might identify protein contact surfaces as novel 
sites of drug action [17] and neural networks help 
drug design [18,19]. Metabolic control analysis (or 
flux-balance analysis) uses a vast set of 
experimental data, and calculates all metabolic rates 
of the metabolic network assuming that the rates of 
reactions producing a metabolite must be equal 
with the rates of reactions, which consume it. These 
methods can highlight key points of the 
metabolism, where a parasite or a pathological 
metabolism can be targeted [20-22]. 
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Figure I. Analysis of drug-induced target inhibition in the context of a network model. 
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 However, most of these methods have been used so 
far to steer target-identification attempts to single 
targets and a systematic analysis of multi-target 
drug action is still to come. Most of the above 
methods are, in principle, appropriate for the 
purpose; however, in most cases an adequate 
analysis appears to depend on too many parameters. 
However, simple topological network models might 
provide some preliminary insight (Box 1). In these 
simplified models, the ‘attack’ on a network, such 
as the genetic regulatory networks of Escherichia 
coli [23] or Saccharomyces cerevisiae [24], is 
modeled by removing or attenuating a target, which 
is either a protein (element), or an interaction (link). 
A comparison of various strategies suggests that 
multiple but partial attacks on carefully selected 
targets are almost inevitably more efficient than the 
knockout of a single, though equally well selected, 
target [6]. For example, the largest damage to the E. 
coli regulatory network is reached by removing an 
element with 72 connections. However, the same 
damage can be attained, if 3 to 5 nodes are partially 
inactivated [6]. A plausible explanation of this 
higher efficiency might be that even partial multi-
target attacks block an increased number of 
individual interactions (network links) than a single 
knockout. Although this poses no problem from the 
practical point of multi-target drug action, 
simulations show that multiple attacks can be more 
efficient than a single attack even if the number of 
affected interactions is the same [6]. Thus, the 
reason underlying the efficiency of multi-target 
attacks is not trivial even from a theoretical point of 
view: multi-target attacks are not only better 
because they affect the network at more sites, they 
can, especially if distributed in the entire network, 
perturb complex systems more than concentrated 
attacks even if the number of targeted interactions 
is the same. Our initial analysis [6] (Box 1) was 
based on network topology, which can fit the case 
of, among others, antimicrobial drugs, where 
network damage corresponds well to the desired 
drug action. For the analysis of multi-target drugs 
that affect specific disease models (e.g. anti-
hypertensive, anti-psychotic and anti-diabetic 
drugs), more specific signaling, metabolic and 
transcriptional network models are needed. 
However, the surprising generality of network 
behavior [11-14], in addition to the successful 
multi-target drugs mentioned earlier suggest that 
there are many highly efficient low-affinity, multi-
target drugs awaiting discovery. The extension of 
current experimental [25-28] and modeling [20-
22,29-33] approaches to perturb networks and 
mimic the effect of multi-target drugs would test 
the generality of our assumptions. 
 
 
Concluding remarks: towards a multi-target 
drug design paradigm 
We propose that drugs with multiple targets might 
have a better chance of affecting the complex 
equilibrium of whole cellular networks than drugs 
that act on a single target. Moreover, it is sufficient 
that these multi-target drugs affect their targets only 
partially, which corresponds well with the 
presumed low-affinity interactions of these drugs 
with several of their targets. Low-affinity, multi-
target drugs might have another advantage. Weak 
links have been shown to stabilize complex 
networks, including macromolecular networks, 
ecosystems and social networks, buffering the 
changes after system perturbations [11,34]. If 
multi-target, low-affinity drugs inhibit their targets, 
they change a strong link into a weak link instead 
of eliminating the link completely. A weak 
activation also results in a weak link in most of the 
cases. Thus, multi-target drugs can increase the 
number of weak links in cellular networks and thus 
stabilize these networks in addition to having 
multiple effects.  
How should we develop multi-target drugs? In 
recent years several experimental and modeling 
approaches have been developed to identify single 
targets in a network context [20-22,25-33]. 
Appropriate modifications of these approaches can 
provide several tools to help identify a suitable set 
of parallel targets and multi-target drug molecules 
for a particular disease. A high-throughput screen 
of the possible combinations can be a formidable 
task. However, the ‘game theory approach’ (where 
the multitude of possible equilibrium conditions is 
simplified by using pre-set rules of the ‘game’) 
might be fruitful to simplify the complex sets of 
equilibrium conditions (with the introduction of 
‘multi-target drug design games’ [34]). 
Additionally, and perhaps most importantly, ‘old 
fashioned’ drug development might come back: if 
you want to know the response of a complex 
system, ‘ask’ the system (by testing drug candidates 
in complex in vivo tests)! And, although microarray 
techniques might be useful to follow multi-target 
drug strategies, in vivo pharmacology (i.e. whole-
animal studies) might become important again [35]. 
Here the ‘story’ goes back to genetics: for more 
efficient in vivo testing, better animal models are 
needed. Better animal models can be achieved by 
‘humanizing’ the metabolism and signaling of test 
animals. Disease target genes and their protein 
products might be transformed from drug targets to 
core elements of better animal models in the future. 
The idea of multi-target attacks is not new. 
Perhaps the first, formal advocate of the multi-
target approach was the military strategist Carl von 
Clausewitz who argued that instead of striving for 
successful single battles, strategy should 
 5
 simultaneously aim at ‘the enemy's forces, his 
resources, and his will to fight’ [36].  His complex 
approach proved to be an efficient antidote to 
Napoleon’s rationally designed campaigns. 
Therefore, we think it is appropriate to conclude – 
paraphrasing another dictum of Clausewitz – that 
multi-target drugs and the network approach might 
become useful as the continuation of drug design 
by other means. 
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